全文获取类型
收费全文 | 29674篇 |
免费 | 4603篇 |
国内免费 | 555篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 466篇 |
妇产科学 | 387篇 |
基础医学 | 1405篇 |
口腔科学 | 663篇 |
临床医学 | 6980篇 |
内科学 | 2016篇 |
皮肤病学 | 140篇 |
神经病学 | 1255篇 |
特种医学 | 332篇 |
外国民族医学 | 1篇 |
外科学 | 3836篇 |
综合类 | 3780篇 |
现状与发展 | 1篇 |
一般理论 | 23篇 |
预防医学 | 6332篇 |
眼科学 | 179篇 |
药学 | 2388篇 |
67篇 | |
中国医学 | 3564篇 |
肿瘤学 | 900篇 |
出版年
2024年 | 183篇 |
2023年 | 945篇 |
2022年 | 1186篇 |
2021年 | 1815篇 |
2020年 | 2047篇 |
2019年 | 1821篇 |
2018年 | 1657篇 |
2017年 | 1732篇 |
2016年 | 1568篇 |
2015年 | 1467篇 |
2014年 | 2229篇 |
2013年 | 2813篇 |
2012年 | 1833篇 |
2011年 | 1962篇 |
2010年 | 1480篇 |
2009年 | 1334篇 |
2008年 | 1382篇 |
2007年 | 1310篇 |
2006年 | 1167篇 |
2005年 | 835篇 |
2004年 | 697篇 |
2003年 | 679篇 |
2002年 | 460篇 |
2001年 | 401篇 |
2000年 | 386篇 |
1999年 | 253篇 |
1998年 | 226篇 |
1997年 | 194篇 |
1996年 | 172篇 |
1995年 | 118篇 |
1994年 | 85篇 |
1993年 | 77篇 |
1992年 | 51篇 |
1991年 | 40篇 |
1990年 | 53篇 |
1989年 | 29篇 |
1988年 | 26篇 |
1987年 | 18篇 |
1986年 | 16篇 |
1985年 | 20篇 |
1984年 | 9篇 |
1983年 | 6篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 10篇 |
1979年 | 5篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 125 毫秒
991.
De Novo Donor‐Specific HLA Antibodies Are Associated With Rapid Loss of Graft Function Following Islet Transplantation in Type 1 Diabetes
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A. M. S. Brooks V. Carter A. Liew H. Marshall A. Aldibbiat N. S. Sheerin D. M. Manas S. A. White J. A. M. Shaw 《American journal of transplantation》2015,15(12):3239-3246
Outcomes after islet transplantation continue to improve but etiology of graft failure remains unclear. De novo donor‐specific human leukocyte antigen (HLA) antibodies (DSA) posttransplant are increasingly recognized as a negative prognostic marker. Specific temporal associations between DSA and graft function remain undefined particularly in programs undertaking multiple sequential transplants. Impact of de novo DSA on graft function over 12 months following first islet transplant was determined prospectively in consecutive recipients taking tacrolimus/mycophenolate immunosuppression at a single center. Mixed‐meal tolerance test was undertaken in parallel with HLA antibody assessment pretransplant and 1–3 months posttransplant. Sixteen participants received a total of 26 islet transplants. Five (19%) grafts were associated with de novo DSA. Five (31%) recipients were affected: three post–first transplant; two post–second transplant. DSA developed within 4 weeks of all sensitizing grafts and were associated with decreased stimulated C‐peptide (median [interquartile range]) at 3 months posttransplant (DSA negative: 613(300–1090); DSA positive 106(34–235) pmol/L [p = 0.004]). De novo DSA directed against most recent islet transplant were absolutely associated with loss of graft function despite maintained immunosuppression at 12 months in the absence of a rescue nonsensitizing transplant. Alemtuzumab induction immunosuppression was associated with reduced incidence of de novo DSA formation (p = 0.03). 相似文献
992.
F. Ausania M. Drage D. Manas C. J. Callaghan 《American journal of transplantation》2015,15(11):2955-2962
Surgical injury to the pancreas is thought to occur commonly during procurement. The UK Transplant Registry was analyzed to determine the frequency of pancreatic injuries, identify factors associated with damage, and assess the impact of injuries on graft survival. Twelve hundred ninety‐six pancreata were procured from donation after brain death donors, with 314 (19.5%) from donation after circulatory death donors. More than 50% of recovered pancreata had at least one injury, most commonly a short portal vein (21.5%). Liver donation, procurement team origin, hepatic artery (HA) arising from the superior mesenteric artery (SMA), and increasing donor BMI were associated with increased rates of pancreas damage on univariate analyses; on multivariate analysis only the presence of an HA from the SMA remained significant (p = 0.02). Six hundred forty solid organ pancreas transplants were performed; 238 had some form of damage. Overall, there was no difference in graft survival between damaged and undamaged organs (p = 0.28); however, graft loss was significantly more frequent in pancreata with arterial damage (p = 0.04) and in those with parenchymal damage (p = 0.05). Damage to the pancreas during organ recovery is more common than other organs, and meticulous surgical technique and awareness of damage risk factors are essential to reduce rates of procurement‐related injuries. 相似文献
993.
Immune Reconstitution Inflammatory Syndrome Secondary to Mycobacterium kansasii Infection in a Kidney Transplant Recipient
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M. Lemoine C. Laurent M. Hanoy J. Leporrier A. François D. Guerrot M. Godin D. Bertrand 《American journal of transplantation》2015,15(12):3255-3258
Nontuberculous mycobacteria (NTM) infection is a challenging diagnosis for clinicians in solid organ transplantation. Immune reconstitution inflammatory syndrome (IRIS) is so far unreported in this context. We report here the case of a renal transplant recipient who developed Mycobacterium kansasii–associated lymphadenitis complicated by IRIS while undergoing reduction of his immunosuppressive therapy. For IRIS, the patient required low‐dose steroids and an increase in global immunosuppression, in association with NTM antibiotherapy. 相似文献
994.
KDIGO Guidelines and Kidney Transplantation: Is the Cystatin‐C Based Recommendation Relevant?
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
I. Masson N. Maillard E. Cavalier E. Alamartine P. Delanaye 《American journal of transplantation》2015,15(8):2211-2214
The KDIGO guidelines propose a new approach to diagnose chronic kidney disease (CKD) based on estimated glomerular filtration rate (GFR). In patients with a GFR value comprised between 45 and 59 mL/min/1.73 m2 as estimated by the CKD‐EPI creatinine equation (eGFRcreat), it is suggested to confirm the diagnosis with a second estimation using the CKD‐EPI cystatin C‐based equations (eGFRcys/eGFRcreat‐cys). We sought to determine whether this new diagnostic strategy might extend to kidney transplant recipients (KTR) and help to identify those with decreased GFR. In 670 KTR for whom a measured GFR was available, we simulated the detection of CKD using the two‐steps approach recommended by the guidelines in comparison to the conventional approach relying on creatinine equation. One hundred forty‐five patients with no albuminuria had eGFRcreat between 45 and 59 mL/min/1.73 m2. Among them, 23% had inulin clearance over 60 mL/min/1.73 m2 and were thus incorrectly classified as CKD patients. When applying the Kidney Disease: Improving Global Outcomes (KDIGO) strategy, 138 patients were confirmed as having a GFR below 60 mL/min with eGFRcreat‐cys. However, 21% of them were misclassified in reference to measured GFR. Our data do no not support the use of cystatin C as a confirmatory test of stage 3 A CKD in KTR. 相似文献
995.
Development and Impact of De Novo Anti‐HLA Antibodies in Pediatric Heart Transplant Recipients
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
C. K. Chen C. Manlhiot T. Allain‐Rooney B. W. McCrindle K. Tinckam A. I. Dipchand 《American journal of transplantation》2015,15(8):2215-2222
There is increasing evidence that de novo anti‐HLA antibodies, more specifically de novo donor‐specific antibodies (DSA) following solid organ transplantation may be associated with negative outcomes including rejection in the first year and graft loss. Limited data are available in pediatric heart transplant recipients. We sought to prospectively determine the incidence, class and early impact of de novo anti‐HLA antibodies in a cohort of pediatric heart transplant recipients. Serial panel reactive antibody testing posttransplant was performed in 25 patients (14 males) transplanted between January 2008 and June 2010. Five patients were sensitized pretransplant; all patients had negative direct crossmatch. Seventy‐two percent developed de novo anti‐HLA antibodies at a median of 2.6 weeks (IQR 1.2 weeks to 6.2 months) posttransplant; 67% of these were DSA. The majority of recipients in our cohort developed de novo anti‐HLA antibodies within the first year posttransplant, with two‐thirds being donor‐specific. Acute cellular rejection, though frequent, was not different in patients with antibody development regardless of class or specificity, and there was no antibody‐mediated rejection, graft loss or early cardiac allograft vasculopathy. 相似文献
996.
R. L. Heilman M. L. Smith S. M. Kurian J. Huskey R. K. Batra H. A. Chakkera N. N. Katariya H. Khamash A. Moss D. R. Salomon K. S. Reddy 《American journal of transplantation》2015,15(8):2143-2151
Our aim was to determine outcomes with transplanting kidneys from deceased donors with acute kidney injury, defined as a donor with terminal serum creatinine ≥2.0 mg/dL, or a donor requiring acute renal replacement therapy. We included all patients who received deceased donor kidney transplant from June 2004 to October 2013. There were 162 AKI donor transplant recipients (21% of deceased donor transplants): 139 in the standard criteria donor (SCD) and 23 in the expanded criteria donor (ECD) cohort. 71% of the AKI donors had stage 3 (severe AKI), based on acute kidney injury network (AKIN) staging. Protocol biopsies were done at 1, 4, and 12 months posttransplant. One and four month formalin‐fixed paraffin embedded (FFPE) biopsies from 48 patients (24 AKI donors, 24 non‐AKI) underwent global gene expression profiling using DNA microarrays (96 arrays). DGF was more common in the AKI group but eGFR, graft survival at 1 year and proportion with IF/TA>2 at 1 year were similar for the two groups. At 1 month, there were 898 differentially expressed genes in the AKI group (p‐value <0.005; FDR <10%), but by 4 months there were no differences. Transplanting selected kidneys from deceased donors with AKI is safe and has excellent outcomes. 相似文献
997.
998.
Donor CD4 T Cell Diversity Determines Virus Reactivation in Patients After HLA‐Matched Allogeneic Stem Cell Transplantation
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
999.
Radioimmunotherapy (90Y‐Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
1000.
The Donor Kidney Biopsy and Its Implications in Predicting Graft Outcomes: A Systematic Review
下载免费PDF全文
![点击此处可从《American journal of transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
C. J. Wang J. B. Wetmore G. S. Crary B. L. Kasiske 《American journal of transplantation》2015,15(7):1903-1914
Despite a growing organ shortage in the United States, many deceased donor kidneys removed for transplantation are discarded. Kidney biopsy findings often play a role in these discards, although it is not clear whether biopsies reliably inform acceptance decisions. Therefore, we carried out a systematic review of the medical literature on the utility of both procurement and implantation biopsies for predicting posttransplant outcomes. Between January 1, 1994 and July 1, 2014, 47 studies were published in the English language literature that examined the association between pretransplant donor biopsy findings from 50 or more donors (with more than half being from deceased donors) and either posttransplant graft failure, delayed graft function, or graft function. In general, study quality was poor. All were retrospective or did not indicate if they were prospective. Results were heterogeneous, with authors as often as not concluding that biopsy results did not predict posttransplant outcomes. The percent glomerular sclerosis was most often examined, and failed to predict graft failure in 7 of 14 studies. Of 15 semiquantitative scoring systems proposed, none consistently predicted posttransplant outcomes across studies. Routine use of biopsies to help determine whether or not to transplant a kidney should be reexamined. 相似文献